AstraZeneca Faces $4.5 Million Fine Over Unpaid Taxes as Q4 Sales Reach $14.9 Billion

On February 6, AstraZeneca announced it has received a notification from Chinese authorities regarding $900,000 in unpaid import taxes related to two of its cancer medications. If the company is found guilty of tax evasion, it could face fines of up to $4.5 million. The investigation has been ongoing since the arrest of the company’s former China president, Wang Lei, in late October 2024, with AstraZeneca assessing the potential impact on key market executives.

In its fourth-quarter earnings report, AstraZeneca confirmed the investigation about the disputed tax amount, which may lead to fines ranging from one to five times the unpaid tax, totaling a maximum of $4.5 million. According to documentation from the Shenzhen Customs, the unpaid taxes pertain to Imfinzi and Imjudo. AstraZeneca stated it will continue to cooperate fully with Chinese authorities.

The news of the investigation has somewhat eased market concerns, with AstraZeneca’s stock in the UK rising nearly 3%. Investors had previously indicated that further selling could occur unless the company disclosed new information regarding the investigation of its executives during the fourth-quarter earnings release.

Wang Lei’s arrest has resulted in scrutiny over AstraZeneca’s operations in China, with over 100 former sales employees under investigation for a major healthcare fraud case. In December, AstraZeneca appointed Iskra Reic as the new head of China operations, taking over from Wang. However, some investors remain skeptical about Reic’s ability to navigate the complexities of the Chinese market during this tumultuous period.

China has long been a key market for AstraZeneca, contributing 13% to the company’s total sales in 2023. The latest financial report indicated that AstraZeneca achieved $14.9 billion in sales for the fourth quarter of 2024, with projections for 2025 sales to exceed analyst expectations.